In Focus

The international organisation is calling for countries with surplus COVID-19 vaccine doses to donate to COVAX.

Opportunities for MNCs exist largely in generics and OTC segments.

Australia faced higher wait times to between 240-365 days for elective surgeries.

Demand for health services is rising in Tier 2 and Tier 3 locations.

Developing nations face inadequate supply as developed nations stockpiled vaccines from top manufacturers.

Although the country has the largest youth population, its number of senior citizens are rising.

The government has allocated 15% of its 2021 budget to healthcare.

The basis for hospital subsidies will be changed to per capita household income.

Human rights issues are seen to have discouraged investment in the region.

Deals in the biopharma sector tripled during the year.

Most local pharma firms hold the research on new drugs as their predominant strategy.

The government is integrating public and private hospitals as the healthcare system is at its breaking point.

Companies have also made investments in R&D as they shift away from generic drugs.

The transition to personalised healthcare is gaining momentum across most of Asia Pacific.

Risk communication emerged as the weakest link during the pandemic.

The country is unable to raise healthcare expenditure by more than 3.8% of GDP, compared to the APAC average of 6.64%.